Antibody responses to two Epstein-Barr virus (EBV) nuclear antigens (EBNA-1 and EBNA-2) during EBV primary infection in children born to mothers infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 23, Issue 4, 1996, Pages 806-808

  Pedneault, Louise ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; VERTICAL TRANSMISSION;

EID: 0029741275     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.4.806     Document Type: Article

References (11)

1. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 1981;41:4222-5.
2. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections andDNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152:876-86.
3. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JLC. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993;81: 1393-403.
4. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Chanock RM, et al., eds. Virology. 2nd ed. New York: Raven Press, 1990:1889-920.
5. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973;11:499-520.
6. Summers WP, Grogan EA, Shedd D, Robert M, Liu C-R, Miller G. Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci USA 1982;79:5688-92.
7. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
8. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84:570-4.
9. Niederman JC, Miller G. Kinetics of the antibody response to BamHI-K nuclear antigen in uncomplicated infectious mononucleosis. J Infect Dis 1986;154:346-9.
10. Miller G, Grogan E, Rowe D, et al. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis 1987;156:26-35.
11. Seigneurin JM, Lavoue MF, Genoulaz O, Bomkamm GW, Lenoir GM. Antibody response against the Epstein-Barr virus-coded nuclear antigen 2 (EBNA2) in different groups of individuals. Int J Cancer 1987;40: 349-53.